Key Highlights Include Data on NUZYRA as an Alternative to Standard of Care to Reduce Clostridioides Difficile Infections and Real-World Experience with NUZYRA for Nontuberculous Mycobacterial and MDR/XDR Gram Negative Infections
Author: brian@
Venatorx Pharmaceuticals to Present Data on Cefepime-Taniborbactam at IDWeek 2020
Malvern, PA, October 21, 2020 – Venatorx Pharmaceuticals today announced that it has two data presentations at IDWeek 2020, which is taking place virtually, starting today through October 25, 2020.
Venatorx Pharmaceuticals Awarded up to $44.2 Million to Advance Novel Inhibitors of Penicillin Binding Proteins targeting WHO Critical Priority Pathogen
Venatorx Pharmaceuticals announced today that it has been awarded a contract by the National Institute of Allergy and Infectious Diseases (NIAID)
Venatorx Pharmaceuticals and GARDP Partner to Develop New Antibiotic for Hospital Acquired Infections With Limited Treatment Options
MALVERN, Pa. & GENEVA–(BUSINESS WIRE)–Venatorx Pharmaceuticals and the Global Antibiotic Research and Development Partnership (GARDP) today announced a collaboration to accelerate the development of, and access to, cefepime-taniborbactam (formerly cefepime/VNRX-5133)
X-BIOTIX Therapeutics Announces Appointment of Michael W. Bonney to its Board of Directors
X-Biotix Therapeutics, Inc. (X-Biotix), a biotechnology company focused on the discovery and development of multiple novel antibiotic first in class compounds targeting multidrug-resistant (MDR) Gram-negative pathogens, announced the appointment of industry veteran, Michael W. Bonney to the company’s Board of Directors.
Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
BOSTON, March 02, 2020 (GLOBE NEWSWIRE) — Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, government and military use, today announced that on February 28,
Paratek Pharmaceuticals to Present at the SVB Leerink 9th Annual Global Healthcare Conference
BOSTON, Feb. 26, 2020 (GLOBE NEWSWIRE) — Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies f
Paratek Announces License Grant to Almirall for SEYSARA® (sarecycline) for Greater China Region
BOSTON, Feb. 24, 2020 (GLOBE NEWSWIRE) — Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, government and military use, today announced the Company has entered into a license grant with Almirall (ALM) for SEYSARA® (sarecycline) for the greater China region, which includes the Peoples Republic...
Paratek Pharmaceuticals to Report Fourth Quarter and Full Year 2019 Financial Results on February 25, 2020
BOSTON, Feb. 13, 2020 (GLOBE NEWSWIRE) — Paratek Pharmaceuticals, Inc. (NASDAQ: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics, today announced the Company will host a conference call and live audio webcast on Tuesday, February 25, 2020 at 4:30 p.m. EDT to report its financial results for the quarter and year ended December 31, 2019 and provide a corporate update.
Paratek Pharmaceuticals Announces Full Year 2019 Total Revenues of $16.5 Million including NUZYRA® (omadacycline) Net Sales of $11.5 Million
BOSTON, Feb. 25, 2020 (GLOBE NEWSWIRE) — Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, government and military use, today reported financial results and provided an update on corporate activities for the fourth quarter and year-ended December 31, 2019.